Pipeline of Congestive Heart Failure Market Review Research for H1 2017 - Reports and Reports
PUNE, India, March 22, 2017 /PRNewswire/ --
ReportsnReports.com adds "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017" to its store providing comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Browse 96 market data tables and 11 figures; spread across 364 pages is available at http://www.reportsnreports.com/reports/917734-congestive-heart-failure-heart-failure-pipeline-review-h1-2017.html .
Companies discussed in this Congestive Heart Failure (Heart Failure) Pipeline Review, H1 2017 report include Allosteros Therapeutics Inc, Amgen Inc, Anexon Inc, AnGes MG Inc, Araim Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Ascelegen Therapeutics Inc, AstraZeneca Plc, Athersys Inc, Bayer AG, BEAT BioTherapeutics Corp, BioCardia Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Capricor Therapeutics Inc, Celixir Ltd, Celyad SA, Daiichi Sankyo Company Ltd, F. Hoffmann-La Roche Ltd, FibroGen Inc, GlaxoSmithKline Plc, Heart Metabolics Ltd , Hemostemix Ltd, Innopharmax Inc, Intrexon Corp, Jiangsu Hengrui Medicine Co Ltd, Juventas Therapeutics Inc, La Jolla Pharmaceutical Company, Lead Discovery Center GmbH, Lee's Pharmaceutical Holdings Ltd, Les Laboratoires Servier SAS, Lonestar Heart Inc, Madeleine Pharmaceuticals Inc, Mast Therapeutics Inc, Merck & Co Inc, Mesoblast Ltd, MorphoSys AG, NanoCor Therapeutics Inc, Neurocrine Biosciences Inc, Novartis AG, Nuo Therapeutics Inc, Nyken BV, Orion Oyj, Palatin Technologies Inc, PharmaIN Corp, PhaseBio Pharmaceuticals Inc, Quantum Genomics SA, Recardio GmbH, RedHill Biopharma Ltd, Renova Therapeutics Inc, scPharmaceuticals Inc, Stealth BioTherapeutics Inc, Stemedica Cell Technologies Inc, Target Heart Biotec Srl, Theravance Biopharma Inc, TiGenix NV, Torrent Pharmaceuticals Ltd, Trevena Inc, U.S. Stem Cell Inc, Vicore Pharma AB and Zensun (Shanghai) Sci & Tech Co Ltd.
Order a Purchase Copy of this Report @ http://www.reportsnreports.com/purchase.aspx?name=917734 .
Scope of this report: The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular). The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure).
The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 28, 16, 2, 32, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 19 and 8 molecules, respectively.
Related Reports:
http://www.reportsnreports.com/reports/917741-epilepsy-pipeline-review-h1-2017.html
http://www.reportsnreports.com/reports/917742-batten-disease-pipeline-review-h1-2017.html
http://www.reportsnreports.com/reports/917744-trigeminal-neuralgia-pipeline-review-h1-2017.html
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact:
Ritesh Tiwari
2nd Floor, Metropole Building,
Next to Inox Theatre,
Bund Garden Road, Pune - 411013.
Maharashtra, India.
+1-888-391-5441
[email protected]
Connect with Us:
LinkedIn: http://www.linkedin.com/company/reportsnreports
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Share this article